Spravato® coming soon!

I plan to offer Spravato® (esketamine) therapy in the near future as part of my commitment to providing effective, evidence-based treatment options for individuals with treatment-resistant depression (TRD).

Spravato® is an FDA-approved antidepressant nasal spray for adults who have not responded to at least two oral antidepressants. Initially authorized in 2019 for use alongside oral antidepressants, Spravato® has now been approved as a standalone treatment following clinical trials demonstrating its effectiveness. Research has shown that Spravato® can lead to significant symptom improvement, with some individuals experiencing relief within just a day or two. This advancement marks an important milestone in psychiatric care, offering a new option for those who have struggled to find relief with traditional treatments.

While esketamine itself is a powerful tool, the process of preparation and integration is just as important in supporting meaningful, lasting healing. When this service becomes available, my approach will include careful screening to determine if Spravato® is an appropriate fit for your needs, intentional preparation to ensure you approach treatment with clarity and safety, and post-treatment integration support to help process any insights or emotions that arise and incorporate them into your ongoing healing.

If you are interested in exploring whether Spravato® may be an option for you in the future, we can discuss it as part of your ongoing care.